Clinical trial
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk
NCT00330733 · VA Office of Research and Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00330733 |
|---|---|
| Title | Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk |
| Official title | Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk |
| Lead sponsor | VA Office of Research and Development, U.S. Fed |
| Collaborators | Joslin Diabetes Center |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Atherosclerosis, Cardiovascular Disease, Inflammation, Insulin Resistance, Noninsulin-dependent Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Salsalate, Placebo |
| Enrollment | 71 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | May 29, 2006 |
| Last update posted | Jan 21, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: